JamesFSimonMD

Fellowship Program Director at Cleveland Clinic

Dr. Simon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Capital Consortium (Walter Reed)Fellowship, Nephrology, 2002 - 2004
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1998 - 2001
Loyola University Chicago Stritch School of MedicineClass of 1998

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

PubMed

SGLT2-Inhibition in Patients With Alport Syndrome.
Jan Boeckhaus, Daniel P Gale, James Simon, Jie Ding, Yanqin Zhang
Kidney International Reports. 2024-12-01
1 citations
Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.
Oliver Gross, Jan Boeckhaus, Lutz T Weber, Hiddo J L Heerspink, James F Simon
Nephrology, Dialysis, Transplantation. 2024-08-09
1 citations
Black Patients Equally Benefit From Renal Genetics Evaluation but Substantial Barriers in Access Exist.
Chloe Borden, Xin Yee Tan, Mary-Beth Roberts, Sarah Mazzola, Fang Zhao
Kidney International Reports. 2023-10-01

Ohio’s Rising Coronavirus Cases Suggest a Fall Surge Is Coming -- Are Northeast Ohio Hospitals Ready?October 26th, 2020
Kidney Patients with Alport Syndrome Are Center of FDA Patient-Focused MeetingAugust 3rd, 2018
What to Do if You Think Your Child Has Flu (Infographic)October 27th, 2016
Join now to see all